Catalyst Pharmaceutical Companions to present summary of CPP-115 compound at epilepsy conference Catalyst Pharmaceutical Companions, Inc www.metformin-hydrochloride.net . announced today that it was selected by both the Scientific and Business Advisory Boards of the Epilepsy Therapy Project to present at the 2010 Epilepsy Pipeline Update Meeting, an in-depth, two day forum to be held February 25-26, 2010, at the Hyatt Embarcadero Hotel in SAN FRANCISCO BAY AREA. Gorodetzky, M.D., Ph.D., Catalyst’s Chief Medical Officer will show a synopsis of CPP-115, Catalyst’s development stage anticonvulsant compound, as a potential treatment for a number of epileptic circumstances, including complicated partial seizures and infantile spasms .
Case management funds breast malignancy screening and diagnostic solutions for low-income women Case management is apparently associated with appropriate follow-up and shorter period to diagnostic quality among low-income women who receive an abnormal result on a mammogram, according to a report in the March 22 problem of Archives of Internal Medication, among the JAMA/Archives journals. Rebecca Lobb, Sc.D., M.P.H., of the Centre for Research on Inner City Health, St. Michael’s Hospital, Toronto, and colleagues studied 2,252 participants in the National Breast and Cervical Cancer Early Detection Program, which funds breast tumor screening and diagnostic providers for low-income, underinsured women.